GlycoMimetics Inc. (Nasdaq: GLYC) reported upbeat updated data from the Phase 1/2 trial for GMI-1271 to treat relapsed/refractory acute myeloid leukemia. The stock price soared $2.13 to close at $16.45.
Upbeat trial data for GlycoMimetics
December 12, 2017 at 18:04 PM EST
